De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
- PMID: 26697766
- DOI: 10.1016/j.berh.2015.09.006
De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
Abstract
As more patients with established rheumatoid arthritis (RA) achieve remission or low disease activity, strategies such as tapering and withdrawal of disease-modifying antirheumatic drugs (DMARDs) are being investigated. In several trials, DMARD discontinuation was associated with a higher risk of relapse, ranging from 56% to 87% at 1 year. Tapering, either by dose reduction or by injection spacing, may limit the risk of relapse. Half-dose etanercept (ETN) versus full-dose continuation was not associated with an increased relapse risk at 1 year in two trials. Progressive antitumor necrosis factor injection spacing was shown to be equivalent to full regimen continuation in terms of persistent flare and disease activity at 18 months in one trial, but not in another one. Reintroduction of a DMARD at previous dose/regimen was usually associated with remission re-induction. The risk of relevant structural damage progression was not increased. Safety improvement has not yet been demonstrated. The annual cost reduction when tapering biologic DMARDs (bDMARDs) was 3500-6000 €/patient. Research questions to be addressed include defining flare that requires reinitiation of treatment, such that patients facilitate the maintenance of remission during tapering by timely communication with their rheumatology team.
Keywords: De-escalation; Dose reduction; Remission; Rheumatoid arthritis; Spacing; Step-down strategy; Treatment discontinuation; Treatment tapering; bDMARD; csDMARD.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.Joint Bone Spine. 2018 Dec;85(6):679-685. doi: 10.1016/j.jbspin.2018.02.002. Epub 2018 Feb 13. Joint Bone Spine. 2018. PMID: 29452300 Review.
-
Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.Rheumatology (Oxford). 2020 Jan 1;59(1):153-164. doi: 10.1093/rheumatology/kez224. Rheumatology (Oxford). 2020. PMID: 31257453 Clinical Trial.
-
[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].Rev Med Interne. 2017 Apr;38(4):256-263. doi: 10.1016/j.revmed.2016.12.014. Epub 2017 Feb 1. Rev Med Interne. 2017. PMID: 28161110 Review. French.
-
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.Lancet Rheumatol. 2024 May;6(5):e268-e278. doi: 10.1016/S2665-9913(24)00021-3. Epub 2024 Apr 4. Lancet Rheumatol. 2024. PMID: 38583450 Clinical Trial.
-
Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.Ann Rheum Dis. 2018 Apr;77(4):515-522. doi: 10.1136/annrheumdis-2017-212423. Epub 2017 Nov 29. Ann Rheum Dis. 2018. PMID: 29187350
Cited by
-
Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable Therapy.ACR Open Rheumatol. 2024 May;6(5):294-303. doi: 10.1002/acr2.11656. Epub 2024 Feb 27. ACR Open Rheumatol. 2024. PMID: 38411023 Free PMC article.
-
Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.Arthritis Res Ther. 2023 Nov 20;25(1):222. doi: 10.1186/s13075-023-03199-0. Arthritis Res Ther. 2023. PMID: 37986101 Free PMC article.
-
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?Nat Rev Rheumatol. 2023 Oct;19(10):611-612. doi: 10.1038/s41584-023-01005-4. Nat Rev Rheumatol. 2023. PMID: 37525010 No abstract available.
-
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.Clin Rheumatol. 2023 Oct;42(10):2777-2786. doi: 10.1007/s10067-023-06659-9. Epub 2023 Jul 7. Clin Rheumatol. 2023. PMID: 37415053 Free PMC article.
-
Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial.Trials. 2022 Jul 27;23(1):600. doi: 10.1186/s13063-022-06543-y. Trials. 2022. PMID: 35897052 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials